<DOC>
	<DOCNO>NCT02921035</DOCNO>
	<brief_summary>This open label , non randomize , uncontrolled , multicenter , single arm observational study . In study , enrol subject treat Rebif human serum albumin ( HSA ) -free formulation ( without RebiSmart ) 44 microgram ( mcg ) , subcutaneous ( sc ) , thrice week ( tiw ) 24 month .</brief_summary>
	<brief_title>Non-interventional Study Assess Adherence Treatment Patients With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Male female subject age equal ( &gt; = ) 18 year less equal ( &lt; = ) 60 year time Rebif introduction Subjects diagnose RMS accord revise McDonald criterion ( 2010 ) Treatment naïve subject DMDs switch Rebif . Subjects receive 1st Rebif 44 mcg dose signing informed consent Subjects willing able provide sign informed consent . Have contraindication treatment IFN beta1a sc accord European summary product characteristic ( EU SPC ) /prescribed information Subjects participate clinical studies/trials Any female subject childbearing potential contraceptive Subjects refusal participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Relapsing Multiple Sclerosis</keyword>
	<keyword>Interferon beta-1a</keyword>
	<keyword>Rebif®</keyword>
	<keyword>Morisky Medication Adherence Scale</keyword>
</DOC>